Bringing the Oncology Community Together

The Future of BRCA1/BRCA2 Testing

Ben Leach
Published Online: Tuesday, January 22, 2013
Ellen T. Matloff

Ellen T. Matloff, MS, CGC

A pair of studies could change the way patients are evaluated for mutations of BRCA1 and BRCA2, two cancer susceptibility genes closely associated with breast and ovarian cancers, as well as other tumor types. From an inexpensive screening method, to extremely accurate next-generation sequencing, the methods described in the studies could allow more patients to be screened and sequenced with greater accuracy at a reduced cost.

Women who inherit harmful BRCA1 and BRCA2 mutations are five times more likely to develop breast cancer over the course of a lifetime, according to the National Cancer Institute. Additionally, women with these mutations are at higher risk of developing early-onset breast and ovarian cancer.

Currently, BRCA1 and BRCA2 mutations are identified through full gene sequencing. Although the existing method is relatively accurate when it comes to identifying mutations, it might not always be able to tell which mutations are actually harmful and could lead to the development of cancer.

Additionally, there are some important limitations with this existing method of sequencing, according to Ellen T. Matloff, MS, CGC, certified genetic counselor and Director of Cancer Genetic Counseling at Yale Cancer Center in New Haven, Connecticut.

“It’s time-consuming,” Matloff said. “It takes approximately three weeks for the results to come back. If you’re testing a newly diagnosed patient, that three weeks can delay any surgical decision-making.”

Matloff said that the cost of the current test is also a concern for many patients. Without insurance, the test costs approximately $4000 per patient, Matloff said.

In a new study published in the journal Cancer Prevention Research, researchers developed a new multiple gene expression profile test that was able to predict whether otherwise healthy women carried harmful BRCA1 or BRCA2 mutations.1

The researchers found that compared with cells from noncarriers, cells with mutations in one or two copies of BRCA1 or BRCA2 had a distinct gene expression profile when exposed to radiation or other causes of DNA damage. The finding could aid researchers in distinguishing healthy mutation carriers from noncarriers.

The researchers collected white blood cells from 9 healthy women with mutated BRCA1 and 8 healthy women with mutated BRCA2 and then exposed them to radiation. After the radiation exposure, the researchers extracted the total RNA from these cells and compared it to RNA that was obtained from white blood cells from 10 healthy noncarrier women that were also exposed to radiation.

The researchers identified approximately 1500 genes that were expressed differently between the BRCA1 and BRCA2 carriers and noncarriers. That list was narrowed down to 18 genes that were most significantly differentiated between the two groups. A validation study using 21 of the differentiated genes and 5 control genes to predict the risk for carrying a mutation was also performed. Finally, blood samples from an independent group of 40 women who were BRCA1 and/or BRCA2 carriers and 17 women who were noncarriers were analyzed. The researchers found that their model had a sensitivity of 95% and 88% specificity.

“This novel technology aims to provide a layer of information regarding the cell functionality aspect of BRCA mutations that could greatly enhance the doctor’s ability to identify high-risk carriers,” said Asher Y. Salmon, MD, a breast cancer specialist at the Hadassah Hebrew University Medical Center in Jerusalem, Israel, and lead author of the study, in a statement. “The current tool for mutation detection is gene sequencing, which is expensive, time-consuming and, in many cases, lacking clear and decisive clinical decision making information. In many cases, the current sequencing tool identifies a mutation, but we do not know if the mutation is neutral or harmful.”

A large validation study is being developed in Europe and North America to assess whether this method of screening is effective in a much larger and heterogeneous population of patients.

Matloff said that because the test is aimed at healthy carriers and noncarriers, she believes it has the potential to reach a wider population while providing very accurate results, and suggests that it could be used as a screening method.

In the second study, published in the European Journal of Human Genetics, researchers from the Catalan Institute of Oncology at the Bellvitge Biomedical Research Institute in Spain developed a comprehensive workflow using next-generation sequencing to improve genetic testing for BRCA1 and 2 mutations. The researchers wanted to find a method that was both cost-effective and utilized next-generation sequencing to improve sensitivity and specificity.2

Although existing methods of sequencing are effective, the researchers noted a couple of limitations. Both BRCA1 and BRCA2 are fairly large genes when it comes to sequencing, and there is a lack of mutation hot spots that are easily identified. They suggested that complementary techniques are required to identify large genomic rearrangements of these genes.

Page: 12Next Page (2) >>
Related Articles
Experts Debate Utility of Genomic Profiling in Daily Practice
Although the potential for next-generation sequencing of breast cancer tumors to improve treatment strategies is widely recognized, questions swirl about the optimal use of such increasingly available technologies in clinical practice for today’s patients.
AR Findings Highlight Detailed Tumor-Profiling Study
A wide-ranging analysis of more than 5500 breast cancer tumors that combined genomic and protein expression testing has identified promising targets to explore for treating patients with poor prognoses, with particularly notable findings involving androgen receptor (AR) expression
Phase III Clinical Trials in HER2-Positive Breast Cancer
Expert panelists explore several large clinical trials examining therapies for patients with HER2-positive breast cancer that are currently ongoing or have recently completed.
Most Popular Right Now
More Reading
External Resources

American Journal of Managed Care
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
OncLive Resources

OncLive TV
Oncology Nurses
Web Exclusives

About Us
Advisory Board
Contact Us
Forgot Password
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.